The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | The future of claudin-18.2 expression analysis in the GEA population
Filip Van Herpe, MD, KU Leuven, Leuven, Belgium, comments on the potential for subgroup analysis in patients with claudin-18.2-positive gastroesophageal adenocarcinoma (GEA), suggesting that further investigation may reveal distinct outcomes in subgroups defined by PD-L1, CPS, and other biomarkers. These findings also have potential to be examined in a larger cohort, including the HER2 population, and to further analyze emerging biomarkers like FGFR2b. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
What we will do is further investigate whether in subgroups we see a little bit more outcomes of the claudin-18.2 population compared to other subsets of PD-L1, CPS, etc. It will be worthwhile in a bigger cohort to explore whether this holds true, for instance, in a HER2 population because the HER2 population was quite slim in its population. And of course, with new emerging biomarkers like FGFR2b, we are already analyzing the same cohort and seeing whether FGFR2b expression is also available in this cohort and probably going to expand the cohort with an additional 300 patients...
What we will do is further investigate whether in subgroups we see a little bit more outcomes of the claudin-18.2 population compared to other subsets of PD-L1, CPS, etc. It will be worthwhile in a bigger cohort to explore whether this holds true, for instance, in a HER2 population because the HER2 population was quite slim in its population. And of course, with new emerging biomarkers like FGFR2b, we are already analyzing the same cohort and seeing whether FGFR2b expression is also available in this cohort and probably going to expand the cohort with an additional 300 patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting or Advisory Role – Merck; Merck/Pfizer
Research Funding – Amgen; Amgen; Astellas Pharma
